GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (XTER:HAEK) » Definitions » Gross Margin %

HAEMATO AG (XTER:HAEK) Gross Margin % : 7.66% (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is HAEMATO AG Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. HAEMATO AG's Gross Profit for the six months ended in Jun. 2023 was €10.2 Mil. HAEMATO AG's Revenue for the six months ended in Jun. 2023 was €133.6 Mil. Therefore, HAEMATO AG's Gross Margin % for the quarter that ended in Jun. 2023 was 7.66%.


The historical rank and industry rank for HAEMATO AG's Gross Margin % or its related term are showing as below:

XTER:HAEK' s Gross Margin % Range Over the Past 10 Years
Min: 6.67   Med: 7.24   Max: 10.78
Current: 7.57


During the past 13 years, the highest Gross Margin % of HAEMATO AG was 10.78%. The lowest was 6.67%. And the median was 7.24%.

XTER:HAEK's Gross Margin % is ranked worse than
93.52% of 988 companies
in the Drug Manufacturers industry
Industry Median: 46.48 vs XTER:HAEK: 7.57

HAEMATO AG had a gross margin of 7.66% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for HAEMATO AG was 6.70% per year.


HAEMATO AG Gross Margin % Historical Data

The historical data trend for HAEMATO AG's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG Gross Margin % Chart

HAEMATO AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.71 6.87 7.42 10.78 8.71

HAEMATO AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.28 10.22 10.02 7.46 7.66

Competitive Comparison of HAEMATO AG's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HAEMATO AG's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's Gross Margin % distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's Gross Margin % falls into.



HAEMATO AG Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

HAEMATO AG's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=21.6 / 248.142
=(Revenue - Cost of Goods Sold) / Revenue
=(248.142 - 226.535) / 248.142
=8.71 %

HAEMATO AG's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=10.2 / 133.638
=(Revenue - Cost of Goods Sold) / Revenue
=(133.638 - 123.395) / 133.638
=7.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


HAEMATO AG  (XTER:HAEK) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HAEMATO AG had a gross margin of 7.66% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


HAEMATO AG Gross Margin % Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


HAEMATO AG (XTER:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (XTER:HAEK) Headlines

No Headlines